Duchenne氏肌肉失養症市場規模、佔有率和成長分析：按治療方法、藥物類別、給藥途徑、分銷管道、最終用戶和地區分類－2026-2033年產業預測

2024 年全球Duchenne氏肌肉失養症市場價值為 234 萬美元，預計從 2025 年的 261 萬美元成長到 2033 年的 628 萬美元，預測期（2026-2033 年）的複合年成長率為 11.6%。

全球Duchenne氏肌肉失養症(DMD) 市場預計將持續成長，這主要得益於對創新治療方法研發投入的增加。這種罕見的遺傳性疾病主要影響男性，會導致嚴重的肌肉無力以及呼吸衰竭和智慧障礙等併發症。目前的治療方法著重於診斷、類固醇治療以及透過幹細胞療法和基因療法等先進技術進行症狀管理。來自各組織和機構的資金投入不斷增加，為全球 150 多家醫療機構提供了津貼，助力其持續開展包括外顯子跳躍療法在內的前沿解決方案研究。對有效治療方法的探索表明，DMD 市場前景良好，預計在未來幾年內改善患者預後並促進市場擴張。

全球Duchenne氏肌肉失養症市場成長要素

受多種因素影響，Duchenne氏肌肉失養症的全球市場正經歷顯著成長。該疾病盛行率的不斷上升促使公眾透過各種宣傳活動提高了對該疾病的認知，這些活動在促進理解和支持方面發揮著至關重要的作用。此外，針對特異性突變的治療方法的進步正在推動該領域的創新。 Exondys51 和 Translarna 等療法的推出，以及不斷擴充的新產品研發管線，進一步推動了市場的動態。同時，皮質類固醇類抗發炎藥物的廣泛應用也擴大了治療選擇，這些因素共同推動了市場成長，並最終改善了患者照護和治療效果。

全球Duchenne氏肌肉失養症市場面臨的限制因素

全球Duchenne氏肌肉失養症）市場面臨許多挑戰，主要原因在於早期診斷困難以及患者因擔心預後而就醫意願下降。評估DMD治療效果十分複雜，因為疾病進展的每個階段都需要不同的療效指標。這是因為許多現有指標缺乏必要的敏感度和客觀性。例如，常用的6分鐘步行測試僅適用於能夠行走的患者，需要大規模樣本大小和長期追蹤研究才能觀察到特定療效。此外，由於缺乏針對年輕患者和無法行走患者的檢驗療效指標，這些患者往往被排除在臨床試驗之外，進一步限制了Duchenne氏肌肉失養症治療市場的發展。

Duchenne氏肌肉失養症的全球市場趨勢

全球Duchenne氏肌肉失養症(DMD) 市場正迅速發展，這主要得益於旨在延緩疾病進展的新藥和創新治療方法的湧現。生技和製藥公司加大研發投入，為潛在治療方法的研發創造了蓬勃發展的環境。此外，患者權益倡導組織的積極支持提高了公眾對該疾病的認知，並簡化了新治療方法的監管核准流程，從而加速了治療方法的普及。這些因素共同推動市場發展，並為患有這種嚴重遺傳疾病的患者及其家庭帶來了更充滿希望的未來。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系圖譜
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球Duchenne氏肌肉失養症市場規模：依治療方法分類

• 基因治療
• 外顯子跳躍療法
• 皮質類固醇
• 終止密碼子通讀療法
• 幹細胞療法
• 其他

全球Duchenne氏肌肉失養症市場規模：依藥物類別分類

• 皮質類固醇
• 反義寡核苷酸
• 小分子藥物
• 基因治療
• 其他

全球Duchenne氏肌肉失養症市場規模：依給藥途徑分類

• 口服
• 靜脈
• 皮下
• 其他

全球Duchenne氏肌肉失養症市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房
• 專科藥房

全球Duchenne氏肌肉失養症市場規模：依最終用戶分類

• 醫院
• 專科診所
• 居家醫療環境
• 研究機構
• 其他

全球Duchenne氏肌肉失養症市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Sarepta Therapeutics Inc.
• PTC Therapeutics Inc.
• Pfizer Inc.
• Roche Holding AG
• F. Hoffmann-La Roche Ltd.
• Sanofi SA
• Novartis AG
• Bristol-Myers Squibb Company
• Biogen Inc.
• AstraZeneca PLC
• Italfarmaco SpA
• Santhera Pharmaceuticals Holding AG
• Nippon Shinyaku Co., Ltd.
• Solid Biosciences Inc.
• Wave Life Sciences Ltd.
• Capricor Therapeutics, Inc.
• Ultragenyx Pharmaceutical Inc.
• Catalyst Pharmaceuticals, Inc.
• ReveraGen BioPharma, Inc.
• Daiichi Sankyo Company, Limited

結論與建議

Global Duchenne Muscular Dystrophy Market size was valued at USD 2.34 Million in 2024 and is poised to grow from USD 2.61 Million in 2025 to USD 6.28 Million by 2033, growing at a CAGR of 11.6% during the forecast period (2026-2033).

The global Duchenne muscular dystrophy (DMD) market is poised for growth, driven by heightened investments in research and development aimed at innovative treatments. This rare genetic disorder predominantly impacts males, leading to significant muscle weakness and associated complications such as respiratory failure and intellectual disability. Currently, therapeutic approaches focus on symptom management through diagnostic care, steroid medications, and advancing techniques like stem cell and gene therapies. Increased funding from organizations and grants to over 150 healthcare institutions worldwide supports ongoing research into cutting-edge solutions, including exon skipping therapies. The commitment to discovering effective treatments indicates a supportive environment for the DMD market, enhancing prospects for improved patient outcomes and market expansion in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Duchenne Muscular Dystrophy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Duchenne Muscular Dystrophy Market Segments Analysis

Global Duchenne Muscular Dystrophy Market is segmented by Therapy Type, Drug Class, Route of Administration, Distribution Channel, End User and region. Based on Therapy Type, the market is segmented into Gene Therapy, Exon Skipping Therapy, Corticosteroids, Stop Codon Read-through Therapies, Stem Cell Therapy and Others. Based on Drug Class, the market is segmented into Corticosteroids, Antisense Oligonucleotides, Small Molecule Drugs, Gene-based Therapies and Others. Based on Route of Administration, the market is segmented into Oral, Intravenous, Subcutaneous and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Specialty Pharmacies. Based on End User, the market is segmented into Hospitals, Specialty Clinics, Homecare Settings, Research Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Duchenne Muscular Dystrophy Market

The global market for Duchenne Muscular Dystrophy is experiencing significant growth due to several influential factors. The increasing prevalence of the disorder has led to heightened awareness through various campaigns, which play a crucial role in promoting understanding and support. Additionally, advancements in mutation-specific therapies are propelling innovation within the sector. A growing pipeline of new products further contributes to market dynamics, alongside the introduction of treatments such as Exondys51 and Translarna. Furthermore, the utilization of corticosteroid-based anti-inflammatory drugs is enhancing treatment options, collectively driving the expansion of this market and improving patient care and outcomes.

Restraints in the Global Duchenne Muscular Dystrophy Market

The Global Duchenne Muscular Dystrophy market faces significant hurdles primarily due to challenges in the timely diagnosis of the condition and a decreased propensity to seek medical intervention influenced by prognosis concerns. The necessity for various outcome measures at different stages of the disease complicates the evaluation of the efficacy of DMD treatments, as many existing measures lack the required sensitivity and objectivity. For instance, the commonly utilized six-minute walk test applies only to ambulant patients, necessitating a large sample size and extended follow-up to observe any tangible benefits. Furthermore, the absence of validated outcome measures for younger and non-ambulant patients often leads to their exclusion from clinical trials, further constraining the market for Duchenne muscular dystrophy treatments.

Market Trends of the Global Duchenne Muscular Dystrophy Market

The global Duchenne Muscular Dystrophy (DMD) market is evolving rapidly, driven by the emergence of novel pharmaceuticals and innovative treatments that aim to modify the disease's progression. Increased investment from biotech and pharmaceutical companies into research and development is fostering a dynamic landscape for potential therapies. Additionally, robust support from patient advocacy organizations is enhancing awareness and streamlining the regulatory approval process for new treatments, thus accelerating their availability. This convergence of factors is propelling the market forward, fostering a more hopeful future for patients and families affected by this severe genetic disorder.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Duchenne Muscular Dystrophy Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Gene Therapy
• Exon Skipping Therapy
• Corticosteroids
• Stop Codon Read-through Therapies
• Stem Cell Therapy
• Others

Global Duchenne Muscular Dystrophy Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Corticosteroids
• Antisense Oligonucleotides
• Small Molecule Drugs
• Gene-based Therapies
• Others

Global Duchenne Muscular Dystrophy Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Intravenous
• Subcutaneous
• Others

Global Duchenne Muscular Dystrophy Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Pharmacies

Global Duchenne Muscular Dystrophy Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare Settings
• Research Institutes
• Others

Global Duchenne Muscular Dystrophy Market Size & CAGR (2026-2033)

• North America (Therapy Type, Drug Class, Route of Administration, Distribution Channel, End User)
  • US
  • Canada
• Europe (Therapy Type, Drug Class, Route of Administration, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Drug Class, Route of Administration, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Drug Class, Route of Administration, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Drug Class, Route of Administration, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Sarepta Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PTC Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Italfarmaco S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santhera Pharmaceuticals Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nippon Shinyaku Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Solid Biosciences Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wave Life Sciences Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Capricor Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ultragenyx Pharmaceutical Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalyst Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ReveraGen BioPharma, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations